UNSPSC 51271635: Ropivacaine hydrochloride

This classification denotes a local anesthetic and amide with the molecular formula C17H26N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V910P86109, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-propyl-, monohydrochloride, (s)- but more generally known as ropivacaine hydrochloride, which bears US NIH Compound Identifier 175804. European Medicines Agency schedules Ropivacaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04264MIG.

UNSPSC 51271635 Ropivacaine hydrochloride is a Commodity code covering local anesthetic pharmaceutical products solicited through state and local cooperative purchasing vehicles. State and local governments procure ropivacaine and related injectable anesthetics for use in hospital systems, surgical centers, and emergency departments, typically through group purchasing agreements that consolidate demand across multiple jurisdictions and facilities. The work here consists of pharmaceutical supply and distribution arrangements rather than clinical services — vendors serve as manufacturers or authorized distributors providing NDC-coded products with specified strength, dosage form, and packaging to meet facility procurement needs.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (RFP S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon, with a response deadline of March 26, 2026. Vendors must supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and maintain contractual relationships with at least two of them with chargeback systems in place. Products must be available in the marketplace by May 15, 2026, with awarded contracts effective July 1, 2026 for a two-year term. Evaluation weights price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing (10 percent), administrative fee compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must certify compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and FDA requirements, maintain insurance coverage including $5 million commercial general liability and $2 million network security and privacy liability, and accept performance penalties of $200 to $1,500 per violation for issues such as late reporting or missed onboarding timelines.